Compare AAME & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | TELA |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7M | 41.3M |
| IPO Year | 1995 | 2019 |
| Metric | AAME | TELA |
|---|---|---|
| Price | $1.71 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 14.1K | ★ 90.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $188,227,000.00 | $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | $7.77 | ★ N/A |
| Revenue Growth | 0.77 | ★ 15.84 |
| 52 Week Low | $1.59 | $0.50 |
| 52 Week High | $3.71 | $2.19 |
| Indicator | AAME | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 40.32 |
| Support Level | $1.59 | $0.67 |
| Resistance Level | $3.15 | $0.75 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 28.00 | 19.29 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.